MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). “We are pleased to progress nintedanib DPI which comes on the heels of furthering our Phase 3 study of Clofazimine Inhalation Suspension for nontuberculous mycobacterial (NTM) lung diseases,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “This puts two studies in motion by mid-year that will explore potential treatment options for patients living with serious lung diseases.” The Phase 1 randomized, double-blind, placebo-controlled, single- (SAD) and multiple-ascending dose (MAD) study wi
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind Outperforms As Tyvaso DPI Captures Market Share [Seeking Alpha]Seeking Alpha
- MannKind (MNKD) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- MannKind Co. (NASDAQ: MNKD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $6.50 price target on the stock.MarketBeat
- Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's Why [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 5/8/24 - Beat
MNKD
Sec Filings
- 5/16/24 - Form 8-K
- 5/14/24 - Form 4
- 5/14/24 - Form 4
- MNKD's page on the SEC website